ALVR - AlloVir Inc Year-over-year net earnings per share growth for the last 12 months

AlloVir, Inc. (ALVR) - corporate logo

AlloVir, Inc. (ALVR) minimizes capital expenditures by relying on external contractors to conduct tests. Current market quotes already price in the search for new development strategies following the closure of old programs. On GURU.Markets, the quarterly earnings per share trend shows that the metric level is 0.00, while high competition in biopharma requires flawless results to protect market positions.

allovir.com (ALVR) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 03/29/2025

Financial and market metric breakdowns for AlloVir, Inc. (ALVR)

- market value and analyst target forecast:
Price Chart allovir.com|ALVR - Fair Value Consensus
- market capitalization statistics:
Market Valuation AlloVir Bio|ALVR - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share AlloVir|ALVR - Book Valuation of Business|Market Capitalization to Book Value Ratio allovir.com|ALVR - Company Total Assets
- debt and liquidity data:
Debt to Equity AlloVir, Inc.|ALVR - Long-Term Debt to Equity|Short-Term Debt to Equity allovir.com|ALVR - Company Debts|Debt to Book Capitalization Ratio AlloVir Bio|ALVR - Long-Term Debt|Company Current Liabilities AlloVir|Quick Ratio allovir.com
- earnings and market multiples details:
ALVR - Net Financial Result|Expected Profit AlloVir, Inc.|ALVR - Company Value to Net Income|Projected Price to Earnings allovir.com|ALVR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple AlloVir Bio|ALVR - Operating income before deduction of amortization|Earnings per share for the last twelve months AlloVir|ALVR - Earnings per share for the last 12 months|Quarterly EPS earnings growth allovir.com|ALVR - Net earnings per share growth this year|Expected earnings per share growth for next year AlloVir, Inc.
- sales and revenue data:
ALVR - Company Gross Revenue|Projected Sales Volume allovir.com|ALVR - P/S Multiple|Price-to-Projected Revenue Ratio AlloVir Bio
Fundamental valuation:AlloVir, Inc.
Manufactured product of allovir.com

This indicator measures the percentage change in net earnings per share between the current and previous quarter, allowing for the identification of the actual business scaling speed and preventing overpayment based on unfounded optimism. By analyzing quarterly EPS dynamics, the investor compares financial returns with the efficiency of the AlloVir, Inc. (ALVR) R&D core, confirming the asset's stability through a consistent workforce.

Analysis of competing companies

Gilead Sciences (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara Corp - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth CureVac Pharma|Year-over-year earnings per share growth for the last twelve months Valneva SE (VALN)|Year-over-year net earnings per share change for the last twelve months vir.bio|Quarterly EPS earnings growth SIGA (SIGA Technologies)|Quarterly EPS earnings growth Emergent BioSolutions Inc EBS|AVIR - Year-over-year earnings per share growth for the last twelve months|IVVD: Year-over-year earnings per share growth for the last twelve months|Enanta Pharmaceuticals (ENTA) - Year-over-year earnings per share growth for the last twelve months|INO (inovio.com) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months HilleVax|Earnings per share growth in annualized terms for the last twelve months Kalaris Therapeutics Inc. KLRS|Year-over-year net earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year earnings per share growth for the last twelve months NNVC (nanoviricides.com)|Quarterly EPS earnings growth TLPH (Talphera, Inc.)|Year-over-year net earnings per share change for the last twelve months cocrystalpharma.com (COCP)|TRAW - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months DWTX (Dogwood Therapeutics, Inc.)|QLGN (Qualigen) - Year-over-year net earnings per share growth for the last 12 months|VBI Vaccines - Year-over-year earnings per one share growth for the last 12 months|VIRI (Virios Therapeutics Inc.) - Quarterly EPS earnings growth|Vaxart Corp (VXRT) - Year-over-year net earnings per share change for the last twelve months